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(1) Summary  
Anthrax is a toxin-mediated disease; the lethal effects of which are initiated by the 
binding of Protective antigen (PA) with one of three reported cell surface toxin 
receptors (ANTXR). Receptor binding has been shown to influence host susceptibility 
to the toxins. Despite this crucial role for ANTXR in the outcome of disease, and the 
reported immunomodulatory consequence of the anthrax toxins during infection, little 
is known about ANTXR expression on human leukocytes. We characterised the 
expression levels of ANTXR1 (TEM8) on human leukocytes using flow cytometry. In 
order to assess the effect of prior toxin exposure on ANTXR1 expression levels, 
leukocytes from individuals with no known exposure, those exposed to toxin through 
vaccination and convalescent individuals were analysed. Donors could be defined as 
either ‘low’ or ‘high’ expressers based on the percentage of ANTXR1 positive 
monocytes detected. Prior exposure to toxins appears to modulate ANTXR1 
expression, exposure through active infection being associated with lower receptor 
expression. A significant correlation between low receptor expression and high 
anthrax toxin-specific IFNγ responses was observed in previously infected individuals. 
We propose that there is an attenuation of ANTXR1 expression post-infection which 
may be a protective mechanism that has evolved to prevent re-infection. 
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(2) Introduction 
Anthrax is a toxin-mediated disease caused infection with by the opportunistic Gram-
positive bacterial pathogen, Bacillus anthracis [1]. The anthrax toxin is a tripartite A–B 
toxin, comprising two alternative A-subunits, lethal factor (LF) and edema factor (EF), 
and a single receptor-binding B-subunit, consisting of heptamers of protective antigen 
(PA).  PA combines with LF to form lethal toxin (LT) or with EF to form edema toxin 
(ET). PA consists of four folding domains [2];domain 1 acts as a binding site for LF or 
EF, domain 2 forms the transmembrane pore and participates in receptor binding while 
domain 3 is involved in heptamerisation and domain 4 binds to the host cell receptor 
[2–4]. PA alone is not toxic and is the principal component of existing licensed vaccines 
for anthrax in the UK and US. 
 
PA binds in a 1:1 ratio [5] with either one of three known cell surface receptors: tumour 
endothelial marker 8 (TEM8 or ANTXR1), capillary morphogenesis protein 2 (CMG2 
or ANTXR2) [6,7] , more recently it was reported that beta1-integrin can also function 
as a receptor [8]. Both ANTXR1 and ANTXR2 are highly expressed in epithelial cells 
lining the sites of entry favoured by B. anthracis - the lungs, skin and intestine [7,9,10]. 
The physiological functions of these receptors are associated with binding to 
extracellular matrix components and are believed to include regulation of endothelial 
cell–matrix interactions, adhesion, migration, cell spreading on collagen and 
angiogenesis [11–13]. 
 
The interaction of the anthrax toxins with their receptors has significant impact on the 
disease process. A mutant cell line lacking ANTXR1/2 is resistant to the effects of 
purified toxin [14], while cells that over express either ANTXR show increased 
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susceptibility to lethal toxin and rapid apoptosis [14,15]. These effects are also seen 
during anthrax infection in vivo: mice supplemented with mutant macrophages lacking 
ANTXR1/2 expression are able to clear a dose of B. anthracis spores which is lethal 
in mice supplemented with wild-type macrophages [16].  
 
Despite the clear role of ANTXR in the disease process [16] and the reported 
immunomodulatory consequence of the anthrax toxins during infection [17], little is 
known about the expression of these receptors on leukocytes. Recently, it has been 
demonstrated that PA preferentially binds NKT cells rather than NK cells or T cells 
[18].  Furthermore, in vitro exposure of macrophages to ET has been shown to 
upregulate mRNA expression of both receptor types [19], whereas mRNA levels for 
ANTXR were down-regulated in the lungs of mice injected intra-nasally with B. 
anthracis Sterne strain spores.   
 
We have previously reported the detailed characterisation of immune responses to 
anthrax toxins in cohorts of naturally infected, vaccinated and unexposed individuals 
[20,21]. These cohorts offer a unique opportunity to determine the modulatory impact 
of prior toxin exposure in vivo in humans in a controlled comparison. Thus, the aim of 
the research presented here was to carry out the first detailed characterisation of the 
surface expression of ANTXR1 on human leukocytes; and more specifically, to assess 
the effect of prior toxin exposure by profiling ANTRX1 expression levels in 
convalescent individuals, by comparison with non-toxin exposed individuals.  
 
 
(3) Materials and Methods 
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Isolation of peripheral mononuclear blood cells from whole blood 
As previously described [21], blood samples were obtained from each of 3 cohorts: 
patients treated for and recovered from cutaneous anthrax (n=10), volunteers routinely 
vaccinated every 12 months for a minimum of 4.5 y with the U.K. Anthrax Vaccine 
Precipitated vaccine (U.K. Department of Health) (n=10), and healthy controls with no 
known exposure to PA or anthrax toxins (UK n = 14, Turkey n = 10).  Full informed 
consent was provided by each subject and ethical approval for the study was granted 
respectively by Ericyes University Ethical Committee, Chemical and Biological 
Defence Independent Ethics Committee for the U.K. Ministry of Defence and the 
Research Ethics Committee reference number 08/H0707/173.  
 
Peripheral blood mononuclear cells (PBMCs) were prepared from sodium heparinized 
blood, using Accuspin tubes (Sigma-Aldrich, Dorset, U.K.), and centrifuged at 800 × g 
for 30 min, after which the cells were removed from the interface and washed twice in 
AIM V serum-free media (GIBCO Invitrogen, Carlsbad, CA).  
 
Antibody and protein conjugation  
Polyclonal TEM8 (ANTXR1), goat IgG isotype control (both Santa Cruz Biotechnology, 
USA) recombinant PA (DSTL, UK) and a control of bovine serum albumin (Sigma, UK) 
were fluorescently labelled using an Alexa Fluor 488 protein-labelling kit (Invitrogen, 
UK) following the manufacturer’s protocol.   
 
Analysis of Anthrax Toxin Receptor 1 expression and Protective Antigen binding by 
flow cytometry 
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Isolated PBMC were washed twice in FACS buffer [PBS (Invitrogen, UK), 10% foetal 
bovine serum (Autogen Bioclear, UK)] by centrifuging at 500 x g for 10 minutes. They 
were then stained with the following antibodies CD56PE, CD3PECy5, CD19 PECy5, 
CD14 PE (all eBioscience, UK), Alex 488 conjugated TEM8 (ANTXR1), IgG isotype 
control, PA or control BSA. All antibodies were used at optimal titrated concentrations 
as recommended by the manufacturers. Post-staining, the cells were washed with 
FACS buffer, fixed with 2% paraformaldehyde and stored at 4°C until analysis.  
Approximately 100,000 events within the lymphocyte gate were acquired using a 
FACScalibur (BD Bioscience, USA) and analysed with FlowJo software (Treestar, 
USA). The lymphocyte and monocyte gates were identified based on their forward/side 
scatter proterties and the cell populations further defined as T cell (CD3+ CD56-), NK 
cells (CD3- CD56+), NKT cells (CD3+ CD56+), B cells (CD19+) and monocytes 
(CD14+). The isotype control antibody or BFA protein binding control were used to 
establish levels of non specific binding and set the gates for positive PA binding or 
ANTXR1 expression (Figure 1A).   
 
Statistical analysis  
As flow cytometric data are inherently non-parametric, the Kruskal-Wallis test, with 
Dunns post hoc testing, was used to compare the levels of PA binding and ANTXR1 
expression level between cell types and cohorts.  During analysis, it could be seen 
that there were distinct groupings of individuals based on the percentage of ANTXR1 
positive monocytes, using the boundaries of these groupings, the populations were 
categorized as low (≤35%) or high (>35%); a comparison of the number of subjects 
falling into each of these categories was made using a two-tail Chi-squared test.  The 
expression levels of ANTXR1 were logged before linear regression analysis with 
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previously published IFNγ responses to PA detected by ELISpot [20] from the same 
individual. Graphpad prism 4.0 software (Graphpad Inc, USA) was used for all 
analyses.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(4) Results  
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A detailed characterization of PBMC for ANTXR1 expression and binding of the 
anthrax toxin component PA was performed (Figure 1A). Although no significant 
differences in the percentage of T, NK and NKT cells binding PA were observed 
(Figure 1B), the median fluorescent intensity (MFI) was significantly higher on NKT 
cells compared to both NK cells (p = 0.02) or T cells (p = 0.008) (Figure 1E).  The 
highest levels of both PA binding and MFI was observed on monocytes (Figure 1D), 
mirrored by a high percentage of monocytes expressing ANTXR1, although B cells 
showed the highest percentage of expression (Figure 1C).  
 
During the analysis of ANTXR1 expression on monocytes, it was apparent that 
individuals could be divided into two main groupings termed ‘low’ and ‘high’ expressers 
(Figure 2A). As ANTXR expression is known to relate to the susceptibility of a cell to 
anthrax toxins (1, 4, 16), it could be hypothesised that the ‘high’ expresser population 
would be more susceptible to anthrax infection. To examine this further, we examined 
ANTXR1 expression levels of the monocytes of individuals who had previously been 
naturally infected with anthrax due to interaction with livestock in an anthrax endemic 
region of Turkey [21]. Contrary to the predicted results, all previously infected 
individuals were categorised as low expressers (Figure 2B, Table 1). In order to ensure 
this wasn’t due to a generic local genetic variation in ANTXR1 expression levels, a 
cohort of local volunteers with no known prior B. anthracis was also examined. There 
was no difference in the percentage of high and low expressers in the unexposed 
volunteers from the UK and Turkey (p=0.63) (Figure 2B, Table 1). However the 
proportion of individuals defined as low or high expressers was significantly different 
in the Turkish individuals based on exposure (p = 0.003) (Table 1), with 60% of the 
unexposed controls defined as high expressers, whilst 100% of the convalescent 
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subjects were low expressers. To establish if the over representation of low expressers 
in the previously exposed subjects was as a result of their exposure to the components 
of the anthrax toxins, a cohort of AVP vaccinated individuals were tested. It was shown 
that there were significantly more ‘high’ expressers (figure 2B, Table 1) compared to 
the UK healthy control cohort (p = 0.008), and the convalescent individuals (p<0.0001) 
(Figure 2B). Futhermore, in a subset of the samples both the percentage of PA binding 
and the median fluorescent intensity (MFI) of PA on the positive cells was measure 
post exposure (Figure 3).    There was a significant reduction in the convalescent 
individuals (n = 4) in both the ppercentage of positive cells and the MFI of PA binding 
comparision to the vaccinated subjects (n = 10) (p = 0.03 and 0.09 respectively), 
however only the percentage of PA binding was reduced in comparison to the 
unexposed controls (n = 7) (p = 0.007). 
 
We have previously published IFNγ ELISpot responses to PA from these cohorts of 
naturally infected and vaccinated individuals [21]. When the response of each 
individual is correlated with their ANTXR1 expression no significant correlation was 
observed (p =0.87, r2 = 0.003) in AVP vaccinated individuals (Figure 4A), even when 
only those individuals who mount an immune response to PA were considered (p = 
0.13, r2 = 0.75). In contrast, there was a significant negative correlation in the naturally 
infected individuals (p = 0.016, r2 = 0.58) (Figure 4B). 
 
 
 
(5) Discussion  
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This study represents the first comprehensive characterization of ANTXR1 expression 
on human leukocytes.  The observation that NKT cells preferentially bind PA 
compared with NK or T cells concurs with previously published research [18]. 
However, PA binding to monocytes was far higher, mirrored by higher percentage of 
cells expressing ANTXR1. Two distinct groups could be identified among our control 
blood donors based on the percentage of ANTXR1 positive  monocytes and these 
were termed ‘low’ and ‘high’ expressers. These results are substantiated by the recent 
demonstration that there is a striking diversity in the sensitivity of human 
lymphoblastoid cell lines to anthrax toxin which results, at least in part, due to 
expression levels of ANTXR2  [22]. Using parent-child trios Martchenko et al [22] 
demonstrated that this variability in expression levels is genetically inherited. It was 
proposed in that study that lethal B. anthracis clades may have exerted evolutionary 
selection pressure on the incidence of toxin receptor polymorphisms in human 
populations. However, we consider it unlikely that anthrax, which is not easily spread 
between humans, has imposed strong selection pressure during human evolutionary 
history.  
 
Given that anthrax toxin receptor expression has been correlated with cell 
susceptibility to the effects of toxin both in vitro and in animal models [14–16,22], we 
postulated ANTXR1 ‘high’ expressers would be more susceptible to either anthrax 
infection or to the development of severe disease. To test this premise, the expression 
levels of ANTXR1 were measured on cells from a cohort of individuals that received 
hospital treatment for cutaneous anthrax infection [21]. As the clinical picture of 
cutaneous anthrax ranges from mild to severe [23] we reasoned that a correlation 
between expression level and the severity of disease would be observed. However, 
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we found that all the exposed and recovered individuals were low expressers. To rule 
out that this was due to some form of generic low expression across this population, 
we also examined local healthy volunteers with no know history of exposure to 
anthrax, but the grouping of unexposed individuals was comparable in the UK and 
Turkish cohorts.  
 
All the Turkish samples were collected by the same clinician, processed by a single 
researcher and analysed under the same flow cytometry conditions, arguing that the 
striking attenuation of ANTXR1 expression on the monocytes of exposed individuals 
is not an artefact of sample preparation or processing. The preponderance of low 
expressers in the exposed cohort could be theorised to result from modulation of 
receptor expression levels by exposure to the anthrax toxin components. Alternatively, 
low expressers may be at increased risk of infection. To examine these postulations, 
we tested a cohort of individuals receiving multiple boosts with AVP vaccine, thus 
exposed to PA, LF and EF without infection. If exposure to these anthrax proteins is 
capable of modulating ANTXR1 expression, then these individuals would also have 
reduced expression of ANTXR1 on their monocytes, whilst if low expression results in 
increased risk of infection, the expression profile of the vaccinated individuals should 
resemble that of the healthy controls. Surprisingly, the AVP vaccinated cohort were all 
classified as high expressers. This divergence in response may be due to the 
concentration and/or ratio in which the infected and vaccinated individuals are 
exposed to the individual anthrax toxin components.  The vaccinees will have been 
primarily exposed to PA, with low concentrations of LF and EF therefore much lower 
toxin concentration than infected individuals. Alternatively, down regulation of 
ANTXR1 may require PA binding within the context of the inflammatory milieu resulting 
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from infection. It has been demonstrated that PA and EF exposure induces an up-
regulation of ANTXR1 in vitro [19], and these condition perhaps more accurately model 
the immunological setting  of vaccination as opposed to the highly inflammatory 
conditions that will be present during a natural infection. The infected individuals also 
received antibiotic treatment at the time of exposure to the anthrax toxins [21] which 
the vaccinated group did not.  We therefore cannot exclude the possibility that the 
therapeutics play a role in the reduction of ANTXR1 levels seen in the convalescent 
cohort.   
 
It is well established that anthrax LT induces pyroptosis in macrophages [24], this rapid 
killing occurs LT activation of the Nlrp1 inflammasome resulting in caspase-1 
activation[25,26], it is therefore possible that this mechanism may have eliminated 
many of the ANTXR1 expressing cells in the cohort of individuals who have been 
previously exposed. It has been suggested that this LT-mediated activation of Nlrp1b 
and subsequent lysis of macrophages may be a protective host-mediated innate 
immune response as opposed to a virulence mechanism exploited by B. anthracis 
[26].  
 
Although we demonstrated that unexposed individuals can be classified as high or low 
expressers based on the percentage of positive monocytes, universally high levels of 
PA binding to these cells was observed.  This is likely to be due to the co-expression 
of ANTXR2 and/or beta1-integrin on the monocytes. Unfortunately due to the logistical 
complexity in obtaining these invaluable convalescent samples it is not feasible to go 
back and reassess the expression of these additional receptors.  The rarity of these 
samples is reflected by the small sample number in which we were able to assess the 
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levels of PA binding.  Despite this, we clearly see that the reduction in ANTXR1 
expression is associated with a reduction both in the percentage of PA positive cells 
and the MFI of PA binding. While ANTXR2 is reported to bind PA with a far greater 
affinity than ANTXR1 [27], the pH at which binding of PA to the receptor occurs also 
differs; with ANTXR1 binding at the more physiologically relevant pH 6.8 in comparison 
to ANTXR2 which binds at pH5.6 [28]. Furthermore, it has been reported that  a mutant 
form of ANTXR1, L56A, performs similarly if not slightly better than ANTXR2 mutants 
in both in vitro and in vivo toxin protection assays [29].  Taken together, this is 
indicative that the reduction in the percentage of monocytes expressing ANTXR1 
could have a biological role in the host response to anthrax toxins. 
 
Individuals in the convalescent cohort were infected at least one year previously, and 
in one case the over 7 years previously [21]. This suggests either that infection causes 
a permanent alteration in the expression of ANTXR1 or that there is ongoing exposure 
without subsequent re-infection which maintains the depressed expression levels, or 
that low-expressers among that population were more likely to become infected in the 
first place.  
 
There was no correlation between the levels of ANTXR1 expression observed within 
this study and the IFNγ response to PA in same AVP vaccinated cohort [21], which 
suggests that a cellular recall response to PA is not related to ANTXR1 expression per 
se. However, only a minority of of vaccinees responded to PA [21], only responsive 
individuals were included in the analysis a much stronger r2 value was observed, this 
was not statistically significant but this may be more reflective of the small number of 
responders. In contrast, in naturally infected individuals a lower percentage of 
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ANTRX1 expression on monocytes significantly correlated with an increased PA T cell 
specific IFNγ response in that individual. Murine models have suggested that IFNγ 
responses by these CD4 T cells are protective against anthrax spores [30].  
 
This is the first documentation of modulation of the expression of ANTXR1 in humans 
due to exposure to anthrax toxins. There is a significant correlation between low 
ANTXR1 expression  and high cellular IFNγ recall responses to PA in individuals 
exposed to toxin in the context of natural infection, suggesting that the attenuation of 
ANTXR1 expression is one of the protective mechanisms to prevent re-infection in 
convalescent cutaneous anthrax patients. 
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Table 1. The percentage of subjects within each cohort defined as ‘low’ or ‘high’ 
expressors of ANTXR1 based on the percentage of positive monocytes detected by 
flow cytometry. 
 
Figure 1; Representative flow cytometry data in a non-exposed control subject are 
shown depicting the levels of PA binding (A top panel) and ANTXR1 expression (A 
bottom panel) on NK cells (CD3- CD56+), NKT cells (CD3+, CD56+), T cells (CD3+, 
CD56-), B cells (CD19+) and monocytes (CD14+). Cells were defined as positive if the 
levels of Alexa488 conjugated PA or ANTXR1 (TEM8) antibody (black line) were 
above the non specific background level of conjugated bovine serum albumin or an 
IgG isotype control respectively (grey line).   The percentage of leukocytes binding PA 
(B) and positive for ANTXR1 (C) in the peripheral blood of health non-anthrax exposed 
volunteers was examined.  The median fluorescent intensity (MFI, an indication of 
levels of binding per cell) of PA binding on NK, NKT and T cell was determined (D).  
PA binding to NKT is significantly higher than binding to T cells or NK cells (p = 0.008 
and p = 0.02 respectively).  However, a higher percentage of B cells and monocytes 
bound PA (D) and monocytes showed a significantly higher ANTXR1 MFI (p = 0.002) 
(E).   
 
Figure 2. The percentage of ANTXR1 positive monocytes in UK healthy volunteers (A) 
and in naturally infected convalescent, vaccinated and unexposed (UK and Turkish) 
individuals (B). 
 
Figure 3. The percentage of monocytes binding PA (A) and the MFI of levels PA in 
naturally infected convalescent (n=4), vaccinated (n=10) and unexposed (UK) 
 20 
 
 
individuals (n=7) was determined by flow cytometery. Significantly lower levels of PA 
binding in the convalescent samples compared to both the unexposed controls and 
the AVP vaccinated individuals (p = 0.03 and 0.007 respectively), while PA MFI was 
significantly lower compare to the AVP vaccinated subjects (p = 0.008) but not 
unexposed controls (p = 0.09).  
 
Figure 4. Whilst there was no significant relationship between the percentage of 
monocytes expressing ANTXR1 and IFN-γ ELISpot responses to PA in AVP 
vaccinated subjects (A),  naturally infected individuals showed an inverse correlation 
between ANTRXR1 expression and IFNγ responses to PA (B), i.e. those individuals 
with the lowest percentage of ANTXR1 positive monocytes showed the highest levels 
of IFN-γ production in response to PA stimulation.  
 
 
 
 
 
 
 
 
 
 
 
Table 1 
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cohort 
Level of ANTXR1 Expression 
Low High 
≤35% >35% 
Naturally infected 100 0 
AVP vaccinated 0 100 
Non-exposed 
(Turkey) 
40 60 
Non-exposed (UK) 50 50 
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